September 6, 2022
COLUMBUS, Ohio – The Ohio State University College of Medicine research funding grew to $367.7 million during the 2022 fiscal year, bolstered by multimillion dollar grants to study traumatic brain injury, gene therapy, and maternal and pediatric medication safety.
College of Medicine research totals are up 22% from the $301.3 million awarded during fiscal year 2021, setting a new funding record. The National Institutes of Health awarded more than $200 million in grants, contracts and subcontracts. The remaining funding came from other government agencies, non-profit foundations and industry contracts.
“Our goal is to pioneer life-altering biomedical discoveries and their translation into breakthrough health care,” said Dr. Carol R. Bradford, dean of the College of Medicine and vice president for Health Sciences at The Ohio State University Wexner Medical Center. “Patients at Ohio State benefit significantly from these discoveries, receiving cutting edge care from some of the most brilliant and compassionate faculty physicians and health care professionals in the nation.”
Aligned with the institution’s research mission and commitment to the investigative process, awards include:
- A $16.1 million grant from the National Institute of Neurological Disorders and Stroke to study inpatient rehabilitation treatments for traumatic brain injuries to identify the specific interventions that are most effective.
- A $14.6 million grant, also from the National Institute of Neurological Disorders and Stroke, to fund a study looking at the safety and efficacy of a novel gene therapy to help children born with a rare genetic disorder called AADC deficiency that causes severe physical and developmental disabilities.
- A five-year $17.1 million grant from the National Institute of Child Health and Human Development that supports the creation of a knowledge bank to support the study of drugs and medical treatments for pregnant and lactating women and children.
Additionally for more than two years, Ohio State scientists have been at the forefront of the COVID-19 pandemic developing new therapies, monitoring for new strains and providing diagnostic services supported by research awards.
“Our faculty and researchers are some of the best in the nation and continue to be at the forefront of biomedical discoveries,” said Peter Mohler, vice president of research at The Ohio State University and chief scientific officer at Ohio State Wexner Medical Center. “We are able to apply what they learn in the labs to create better treatments and advance health care not just here in central Ohio but throughout the world.”
Ohio State’s fiscal year 2022 research portfolio includes 98 new awards over $1 million. In all, there are more than 3,000 active awards, a 6.2% increase from fiscal year 2021.
Media Contact: Serena Smith, Wexner Medical Center Media Relations, Serena.Smith@osumc.edu